Application of physiologically-based pharmacokinetic modeling to investigate the toxicological interaction between chlorpyrifos and parathion in the rat

被引:17
|
作者
El-Masri, HA [1 ]
Mumtaz, MM [1 ]
Yushak, ML [1 ]
机构
[1] ATSDR, Div Toxicol, Computat Toxicol Lab, Atlanta, GA 30333 USA
关键词
chlorpyrifos; parathion; PBPK; interaction threshold;
D O I
10.1016/j.etap.2003.10.002
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Environmental exposure is usually due to the presence of multiple chemicals. In most cases, these chemicals interact with each other at both pharmacokinetic and pharmacodynamic toxicity mechanisms. In the absence of data, joint toxicity assessment of a mixture is based on default dose or response additivity. Although, the concept of additivity is mostly accepted at low dose levels, these levels need to be determined quantitatively to validate the use of additivity as an absence of any possible synergistic or antagonistic interactions at low environmental exposure levels. The doses at which interaction becomes significant define the interaction threshold. In most cases, estimation of these low-dose interaction thresholds experimentally is economically costly and challenging because of the need to use a large number of laboratory animals. Computational toxicology methods provide a feasible alternative to establish interaction thresholds. For example, a physiologically based pharmacokinetic (PBPK) model was developed to estimate an interaction threshold for the joint toxicity between chlorpyrifos and parathion in the rat. Initially, PBPK models were developed for each chemical to estimate the blood concentrations of their respective metabolite. The metabolite concentrations in blood out-put was then linked to acetylcholinesterase kinetics submodel. The resulting overall PBPK model described interactions between these pesticides at two levels in the organism: (a) the P450 enzymatic bioactivation site, and (b) acetylcholinesterase binding sites. Using the overall model, a response surface was constructed at various dose levels of each chemical to investigate the mechanism of interaction and to calculate interaction threshold doses. The overall model simulations indicated that additivity is obtained at oral dose levels below 0.08 mg/kg of each chemical. At higher doses, antagonism by enzymatic competitive inhibition is the mode of interaction. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:57 / 71
页数:15
相关论文
共 50 条
  • [1] Physiologically-based pharmacokinetic modeling of pyrene in the rat
    Haddad, S
    Withey, J
    Laparé, S
    Law, F
    Krishnan, K
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 1998, 5 (04) : 245 - 255
  • [2] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR PREGNANCY
    Liu, X.
    Leong, R.
    Buckart, G.
    Dallmann, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S117 - S117
  • [3] Application of physiologically-based pharmacokinetic modeling in hepatic impairment populations
    Sager, Jennifer
    Hsu, Matt
    Isoherranen, Nina
    Wienkers, Larry
    Wahlstrom, Jan
    Foti, Robert
    FASEB JOURNAL, 2014, 28 (01):
  • [4] Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
    Liu, Hongrui
    Yu, Yiqun
    Liu, Lu
    Wang, Chunyan
    Guo, Nan
    Wang, Xiaojuan
    Xiang, Xiaoqiang
    Han, Bing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Pharmacokinetics and Physiologically-Based Pharmacokinetic Modeling of Nanoparticles
    Yang, Raymond S. H.
    Chang, Louis W.
    Yang, Chung Shi
    Lin, Pinpin
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2010, 10 (12) : 8482 - 8490
  • [6] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING AND BIOACTIVATION OF XENOBIOTICS
    CLEWELL, HJ
    ANDERSEN, ME
    TOXICOLOGY AND INDUSTRIAL HEALTH, 1994, 10 (1-2) : 1 - 24
  • [7] PHYSIOLOGICALLY-BASED MODELING OF THE TOXICOKINETIC INTERACTION BETWEEN TOLUENE AND M-XYLENE IN THE RAT
    TARDIF, R
    LAPARE, S
    KRISHNAN, K
    BRODEUR, J
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1993, 120 (02) : 266 - 273
  • [8] Application of Physiologically-Based Oral Absorption & Pharmacokinetic Modeling to Investigate Formulation Factors Influencing the Pharmacokinetics of Novel Oral Anticoagulants
    Farhan, Nashid
    Basu, Sumit
    Kim, Sarah
    Lingineni, Karthik
    Vozmediano, Valvanera
    Ait-Oudhia, Sihem
    Fang, Lanyan
    Zhao, Liang
    Lesko, Lawrence
    Schmidt, Stephan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S82 - S82
  • [9] Application of physiologically-based pharmacokinetic modeling to inform dosing decisions for geriatric patients
    Qian, Lixuan
    Wang, Ziteng
    Paine, Mary F.
    Chan, Eric Chun Yong
    Zhou, Zhu
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024,
  • [10] Endocytosis mechanism in physiologically-based pharmacokinetic modeling of nanoparticles
    Deng, Linjing
    Liu, Hui
    Ma, Yongsheng
    Miao, Yufeng
    Fu, Xiaoli
    Deng, Qihong
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 384